Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort

Schnitzler, F.; Fidder, H.; Ferrante, M.; Noman, M.; Arijs, I.; Van Assche, G.; Hoffman, I.; Van Steen, K.; Vermeire, S.; Rutgeerts, P.
April 2009
Gut;Apr2009, Vol. 58 Issue 4, p492
Academic Journal
Background and aims: This observational study assessed the long-term clinical benefit of infliximab (IFX) in 614 consecutive patients with Crohn's disease (CD) from a single centre during a median follow-up of 55 months (interquartile range (IQR) 27-83). Methods: The primary analysis looked at the proportion of patients with initial response to IFX who had sustained clinical benefit at the end of follow-up. The long-term effects of IFX on the course of CD as reflected by the rate of surgery and hospitalisations and need for corticosteroids were also analysed. Results: 10.9% of patients were primary non-responders to IFX. Sustained benefit was observed in 347 of the 547 patients (63.4%) receiving long-term treatment. In 68.3% of these, treatment with IFX was ongoing and in 31.7% IFX was stopped, with the patient being in remission. Seventy patients (12.8%) had to stop IFX due to side effects and 118 (21.6%) due to loss of response. Although the yearly drop-out rates of IFX in patients with episodic (10.7%) and scheduled treatment (7.1%) were similar, the need for hospitalisations and surgery decreased less in the episodic than in the scheduled group. Steroid discontinuation also occurred in a higher proportion of patients in the scheduled group than in the episodic group. Conclusions: In this large real-life cohort of patients with CD, long-term treatment with IFX was very efficacious to maintain improvement during a median follow-up of almost 5 years and changed disease outcome by decreasing the rate of hospitalisations and surgery.


Related Articles

  • Infliximab.  // Reactions Weekly;10/16/2010, Issue 1323, p25 

    The article describes the cases of two women who developed Lewis-Summer syndrome (LSS) while receiving treatment with infliximab for Crohn's disease (CD).

  • Infliximab.  // Reactions Weekly;5/15/2010, Issue 1301, p29 

    The article describes the case of two men who developed fulminant legionellosis after being given infliximab as treatment for Crohn's disease.

  • Individualized Therapy Is a Long-Term Cost-Effective Method Compared to Dose Intensification in Crohn's Disease Patients Failing Infliximab. Steenholdt, Casper; Brynskov, Jørn; Thomsen, Ole; Munck, Lars; Fallingborg, Jan; Christensen, Lisbet; Pedersen, Gitte; Kjeldsen, Jens; Jacobsen, Bent; Oxholm, Anne; Kjellberg, Jakob; Bendtzen, Klaus; Ainsworth, Mark // Digestive Diseases & Sciences;Sep2015, Vol. 60 Issue 9, p2762 

    Background: In Crohn's disease patients failing infliximab therapy, interventions defined by an algorithm based on infliximab and anti-infliximab antibody measurements have proven more cost-effective than intensifying the infliximab regimen. Aim: This study investigated long-term economic...

  • New Relief for Crohn's Disease. Harrar, Sari; Metcalf, Eric // Prevention;Mar2002, Vol. 54 Issue 3, p155 

    Reports that the steroid drug budesonide is effective in treating Crohn's disease flare-ups and has fewer side effects than prednisone, the conventional therapy.

  • Controversies in the treatment of Crohn's disease: The case for an accelerated step-up treatment approach. Shergill, Amandeep K.; Terdiman, Jonathan P.; Wexner, Steven D.; Duchmann, Rainer J. // World Journal of Gastroenterology;5/7/2008, Vol. 14 Issue 17, p2670 

    The ideal treatment strategy for Crohn's disease (CD) remains uncertain, as does the optimal endpoint of therapy. Top-down versus step-up describes two different approaches: early use of immunomodulators and biological agents in the former versus initial treatment with steroids in the latter,...

  • Healing of Crohn's disease enterovesical fistula, with the use of infliximab: a case report. Steinwurz, Flavio // American Journal of Gastroenterology;Sep2003 Supplement, Vol. 98, pS238 

    An abstract of the article concerning infliximab treatment of Crohn's disease is presented.

  • Infliximab treatment for Crohn's disease treated with elemental diet: the Tokyo experience. Tanaka, Torao; Takazoe, Masakazu; Morita, Eijirou; Terabe, Fumitaka // American Journal of Gastroenterology;Sep2003 Supplement, Vol. 98, pS252 

    An abstract of the article concerning infliximab treatment with elemental diet for Crohn's disease is presented.

  • Treatment of cutaneous Crohn's disease with infliximab. Mitchell, Sara H; Varano, Vincent J; Komar, Michael J // American Journal of Gastroenterology;Sep2003 Supplement, Vol. 98, pS250 

    An abstract of the article concerning infliximab treatment of cutaneous crohn's disease is presented.

  • Economic benefit of algorithm-based therapy after IFX failure.  // PharmacoEconomics & Outcomes News;Feb2015, Vol. 722 Issue 1, p14 

    The article reports on the Danish research indicating the economic advantage of individualised algorithm-based therapy after the failure of infliximab (IFX) in treating patients suffering from Crohn's disease.


Read the Article


Sign out of this library

Other Topics